Advertisement

Intensification de la chimiothérapie en consolidation

  • H. Curé
  • J.-O. Bay
  • B. Choufi
  • P. Chollet
Part of the Abord clinique book series (ONCOLPRAT)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Omura GA, Brady MF, Homesley HD et al. (1991) Long term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 9: 1138–50PubMedGoogle Scholar
  2. 2.
    Van Der Burg MEL, van Lent M, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy ont the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332: 629–34PubMedGoogle Scholar
  3. 3.
    Nelson BE, Rosenfield AT, Schwartz PE (1993) Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 11: 166–72PubMedGoogle Scholar
  4. 4.
    Mc Guire WP, Hoskins WJ, Brady MF et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cacner. N Engl J Med 334: 1–6Google Scholar
  5. 5.
    Spano JP, Lucchi E, Sezeur A et al. (1998) Les tumeurs épithéliales malignes de l’ovaire (stade avancé). Bull cancer, suppl FMC 2: 5–23Google Scholar
  6. 6.
    Curé H (2004) Dose intensity in the treatment of advanced epithelial ovarian cancer: in Gynecologic cancer: Controversies in management. Gerhenson DM et al. Elsevier 479–89Google Scholar
  7. 7.
    Skipper HE (1990) Dose intensity versus total dose of chemotherapy: an experimental basis. In: Importance Advance in Oncology. De Vita VT, Hellman S, Rosenberg SA (Ed.). J.B. Lippin-cott 43–64Google Scholar
  8. 8.
    Norton L, Simon R (1977) Tumor size, sensitivity to therapy, and design of treatment schedule. Cancer Treat Rep 61: 1307–17PubMedGoogle Scholar
  9. 9.
    Goldie JH, Goldman AJ, Gudauskas GA (1982) Rationale for the use of alternating crossresistant chemotherapy. Cancer Treat Rep 66: 439–49PubMedGoogle Scholar
  10. 10.
    Rubin SC (1993) Second laparotomy in ovarian cancer. Cancer of the ovary. Markmann M., Hoskins WJ (Eds.). Raven Press Ltd, New-YorkGoogle Scholar
  11. 11.
    Levin L, Hryniuk WM (1987) Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5: 756–67PubMedGoogle Scholar
  12. 12.
    Jodrell DI, Egorin MJ, Canetta RM et al. (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10: 520–8PubMedGoogle Scholar
  13. 13.
    Ben-David Y, Rosen B, Franssen E et al. (1995) Meta-analysis comparing cisplatin total dose intensity and survival. Gynecol Oncol 59: 93–101CrossRefPubMedGoogle Scholar
  14. 14.
    Kaye SB, Paul J, Cassidy J et al. (1996) Mature results of randomized trial of two doses of cisplatine for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol 14(7): 2113–9PubMedGoogle Scholar
  15. 15.
    Ngan HY, Choo YC, Cheung M et al. (1989) A randomized study of high-dose versus lowdose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group. Chemotherapy 35: 221–7PubMedGoogle Scholar
  16. 16.
    Murphy D, Crowther D, Renninson J et al. (1993) A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. Ann Oncol 4: 377–83PubMedGoogle Scholar
  17. 17.
    Bella M, Cocconi G, Lottici R et al. (1994) Mature results of a prospective randomized trial comparing two different dose-intensity regimens of cisplatin in advanced ovarian carcinoma. Ann Oncol 5(suppl 8): 2Google Scholar
  18. 18.
    McGuire WP, Hoskins WJ, Brady MF et al. (1995) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 13: 1589–99PubMedGoogle Scholar
  19. 19.
    Rothenberg ML, Ozols RF, Glatstein E et al. (1992) Dose-intensive induction therapy with cyclophosphamide, cisplatin and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol 10: 727–34PubMedGoogle Scholar
  20. 20.
    Grem J, O’Dwyer P, Elson P et al. (1991) Cisplatin, carbo-platin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: en Eastern Cooperative Oncology Group pilot study. J Clin Oncol 9: 1793–800PubMedGoogle Scholar
  21. 21.
    Piccart MJ, Nogaret JM, Marcelis L et al. (1990) Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma. J Natl Cancer Inst 82: 703–7PubMedGoogle Scholar
  22. 22.
    Fanning J, Hilgers RD (1993) High dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer. Gynecol Oncol 51: 182–6CrossRefPubMedGoogle Scholar
  23. 23.
    Joly F, Heron JF, Kerbrat P et al. (2000) High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French comprehensive cancer centers (FNCLCC). Gynecol Oncol 78(3 Pt 1): 361–8PubMedGoogle Scholar
  24. 24.
    Thigpen T (1995) High-dose chemotherapy with autologous bone marrow support in ovarian carcinoma: the bottom line, more or less (Editorial). Gynecol Oncol 57:275–7PubMedGoogle Scholar
  25. 25.
    Cain JM, Ellis GK, Collins C et al. (1990) Bone marrow involvment in epithelial ovarian cancer by immunocytotechnical assessment. Gynecol Oncol 38: 442–5CrossRefPubMedGoogle Scholar
  26. 26.
    Ron AA, Miller GW, Moss TJ et al. (1995) Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer. Bone Marrow Transplant 15: 929–33Google Scholar
  27. 27.
    Dal Cortivo L, Cottu PH, Lotz JP et al. (2001) Residual tumor cell contamination in peripheral blood stem cells collections of 117 breast cancer patients evaluated by immunocytochemical technique. J Hematother Stem Cell Res 10(6): 855–62Google Scholar
  28. 28.
    Pujade-Lauraine E, Cure H, Battista C et al. (2001) High dose chemotherapy in ovarian cancer Int J Gynecol Cancer 11 (Suppl 1): 64–7Google Scholar
  29. 29.
    Curé H, Extra JM, Viens P et al. (2000) High-dose chemotherapy as consolidation therapy for patients with platinum-sensitive advanced epithelial ovarian cancer. Bone Marrow Transplantation 26(1): S27–S29Google Scholar
  30. 30.
    M. Legros†, J. Dauplat, J. Fleury et al. (1997) J Clin Oncol 15: 1302–8Google Scholar
  31. 31.
    Extra JM, Curé H, Viens P et al. (1993) High dose chemotherapy with autologous bone marrow transplantation in ovarian adeno-carcinoma. Bull Cancer 80: 156–62PubMedGoogle Scholar
  32. 32.
    Curé H, Battista C, Guastalla JP et al. (2001) Phase III randomized trial of high-dose (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC): preliminary results of a GINECO/FNCLCC/SFGM-TC study. Proc Am Soc Clin Oncol 20, abstract 815Google Scholar
  33. 33.
    Curé H, Battista C, Guastalla JP et al. (2004) Phase III randomized trial of high-dose (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC): preliminary results of a GINECO/FNCLCC/SFGM-TC study. Proc Am Soc Clin Oncol 23, abstract 5006Google Scholar
  34. 34.
    Ledermann J, Herd R, Maraninchi D et al. (2001) High dose chemotherapy for ovarian carcinoma: long-term results from the solid tumour registry of the European Group for blood and Marrow Transplantation (EBMT). Annals of Oncology 12: 693–9CrossRefPubMedGoogle Scholar
  35. 35.
    Shpall EJ, Cagnoni PJ, Bearman SI et al. (1995) High dose chemotherapy with autologous hematopoietic cell support (AHCS) for the treatment of epithelial ovarian cancer. 31st Annual Meeting of the American Society of Clinical Oncology, Los Angeles, Ca (USA), May 20-23 (Educational Book) pp. 360–4Google Scholar
  36. 36.
    Stiff P, Bayer R, Camarda M (1995) A phase II trial of high-dose mitoxantrone, carboplatine and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. Gynecol Oncol 57: 278–85CrossRefPubMedGoogle Scholar
  37. 37.
    Stiff P, Bayer R, Kerger C et al. (1997) High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 4: 1309–17Google Scholar
  38. 38.
    Shinozuka T, Miyamoto T, Muramatsu T et al. (1999) High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: long term results for 105 patients. Cancer 85(7): 1555–64CrossRefPubMedGoogle Scholar
  39. 39.
    Curé H, D’Incan C, Bignon YJ et al. (1997) Immunothéapie du cancer de l’ovaire, passé, présent, futur. Références en gynécologie obstétrique 5(2): 161–8Google Scholar
  40. 40.
    Pujade-Lauraine E, Guastalla JP, Colombo N et al. (1996) Intraperiotoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second look laparotomy. J Clin Oncol 14: 343–50PubMedGoogle Scholar
  41. 41.
    Faradji A, Bohbot A, Frost H et al. (1991) Phase I of liposomal MTP-PE activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis. J Clin Oncol 9: 1251–60PubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • H. Curé
  • J.-O. Bay
  • B. Choufi
  • P. Chollet

There are no affiliations available

Personalised recommendations